Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
Bausch + Lomb said a constructive FDA meeting gave it clarity on the development path for BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration. The FDA supported the proposed initial study design in principle, and the company plans to start the clinical program in 2027, with a Phase 2 study in earlier-stage dry AMD patients to follow barring unexpected findings.
Key figures
- Drug Name
- BL1243 (tonabersat)
- Phase Of Trial
- Phase 1 (initial study) with planned Phase 2
- Prior dose studied
- 80 mg oral tonabersat
- Clinical program start
- 2027
- Prior clinical exposure
- ~2,100 people
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.